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Abstract
Background: Many patients have uncontrolled blood pressure (BP) because they are not taking medications as
prescribed. Providers may have difficulty accurately assessing adherence. Providers need to assess medication
adherence to decide whether to address uncontrolled BP by improving adherence to the current prescribed
regimen or by intensifying the BP treatment regimen by increasing doses or adding more medications.
Methods: We examined how provider assessments of adherence with antihypertensive medications compared
with refill records, and how providers’ assessments were associated with decisions to intensify medications for
uncontrolled BP. We studied a cross-sectional cohort of 1169 veterans with diabetes presenting with BP ≥140/90 to
92 primary care providers at 9 Veterans Affairs (VA) facilities from February 2005 to March 2006. Using VA pharmacy
records, we utilized a continuous multiple-interval measure of medication gaps (CMG) to assess the proportion of
time in prior year that patient did not possess the prescribed medications; CMG ≥20% is considered clinically
significant non-adherence. Providers answered post-visit Likert-scale questions regarding their assessment of patient
adherence to BP medications. The BP regimen was considered intensified if medication was added or increased
without stopping or decreasing another medication.
Results: 1064 patients were receiving antihypertensive medication regularly from the VA; the mean CMG was
11.3%. Adherence assessments by providers correlated poorly with refill history. 211 (20%) patients did not have BP
medication available for≥ 20% of days; providers characterized 79 (37%) of these 211 patients as having significant
non-adherence, and intensified medications for 97 (46%). Providers intensified BP medications for 451 (42%)
patients, similarly whether assessed by provider as having significant non-adherence (44%) or not (43%).
Conclusions: Providers recognized non-adherence for less than half of patients whose pharmacy records indicated
significant refill gaps, and often intensified BP medications even when suspected serious non-adherence. Making an
objective measure of adherence such as the CMG available during visits may help providers recognize
non-adherence to inform prescribing decisions.
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Background
Non-adherence with blood pressure (BP) medications is
commonly cited as a cause of uncontrolled hyperten-
sion, and BP medication non-adherence is associated
with worse outcomes [1,2]. Physicians frequently need to
decide if the patient’s BP is too high because the patient
isn’t taking medications as prescribed, or if the patient’s
current BP prescription needs intensification. Unfortu-
nately, healthcare providers can have difficulty making this
decision because BP medication adherence problems can
be difficult for providers to detect [3-6]. Adherence pro-
blems lead to suboptimal control of hypertension in two
ways: the patient does not take medications as prescribed
and the possibility of non-adherence increases the uncer-
tainty faced by physicians in deciding medication changes
[7,8]. This common clinical quandary inspired the follo-
wing research questions:
1. How often do providers correctly identify patients
with poor adherence to chronic BP medications?
2. When BP is uncontrolled, how often do providers
intensify the medication regimen for patients that
providers believe have significant non-adherence with
BP medications?
To address these questions, we used data from the
ABATe (Addressing Barriers to Treatment of Hyperten-
sion) study [9], designed to examine treatment change
decisions for diabetic primary care patients with elevated
triage BP (≥ 140/90) at primary care visits. We hypothe-
sized that many patients who presented with uncontrolled
BP would have pharmacy refill patterns that supported
non-adherence by late refill requests. Because non-
adherence can be difficult for providers to recognize [3-5],
we also hypothesized that many primary care providers
would not recognize non-adherence in their patients. Yet,
we expected that when primary care providers did re-
cognize significant medication non-adherence, they would
be less likely to respond to elevated BP by intensifying the
medication regimen by either increasing the dose(s) or
prescribing extra medications.
Methods
Design and participants
We performed an analysis of medication adherence using
information collected in a larger cross-sectional cohort
study [9] of patients scheduled for primary care visits with
92 primary care providers at 9 Department of Veterans
Affairs (VA) facilities of varied sizes in 3 mid-western
states. The institutional review boards of all participating
VA facilities approved the study protocol; the VA institu-
tional review board policies are based on The Common
Rule (45 CFR 46, Subpart A) governing research, rooted
in several US and international research ethics guidelines,
including the Helsinki Declaration. All recruited patients
had diabetes, their lowest BP in triage was ≥140/90, and
the patients had identified the VA as their primary source
of care for diabetes. Of note, by clinic triage policies, a se-
cond blood pressure measurement should be obtained
if the first blood pressure was elevated; patients were
eligible if their lowest triage systolic blood pressure was
140 mmHg or greater or if their lowest diastolic blood
pressure was 90 mmHg or greater. Patients with impaired
decision-making ability, terminal disease, residents of
nursing homes, and those who did not speak English were
excluded. As detailed in Figure 1, of the 1556 patients
approached by study staff, 213 were ineligible; 1169
patients and their providers signed written consent. The
analyses in this paper focus on the 1064 patients who had
at least one chronic BP medication refilled at the VA.
Data sources
Our analyses utilized 4 data sources. First, VA automated
data sources were used to obtain BP values at the time
of study enrollment. Second, VA pharmacy records for
1 year prior and 90 days after enrollment provided the
total number of medications, and the number and refill
history for antihypertensive medication classes. Third,
providers completed a brief survey for each patient after
the same clinic session in which they saw the patient
(completion rate, 99%). Fourth, patients completed a brief
questionnaire after the visit including self-report of socio-
demographic characteristics including age, race/ethnicity,
annual income, and monthly prescription costs.
Measurements
1. Refill adherence measure
For our refill adherence measure, we used the Continuous
Multiple-interval Gap (CMG) measure because it has
been used previously to assess VA pharmacy data inclu-
ding antihypertensive medications [10-12], and has been
assessed in comparison with electronic pill cap monitoring
studies [13] which is as close to a ‘gold standard’ of medi-
cation adherence currently possible regarding hyperten-
sion treatment. In brief, the CMG measure uses pharmacy
data (including fill and refill dates, quantities, daily doses)
to determine how many days over the past year the patient
did not possess BP medications to take as prescribed,
expressed as a percentage of days in past year. For exam-
ple, a CMG of 20% means the patient refilled the medi-
cation in a manner that left 20% of days without an
adequate medication supply to take. The CMG can also
be interpreted as a proportion of time the patient misses
their medications, with a CMG of 20% meaning that on
average, the patient missed 20% of the doses, or 1 dose in
5. Prior literature has established that a lack of medication
possession of ≥ 20% is clinically significant refill non-
adherence [11,14,15]. Of note, for medications prescribed
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for multiple doses per day, it is possible that a patient
could still be taking some but inadequate doses of medica-
tion each day. For example, a patient taking a twice daily
antihypertensive medication could have a CMG of 50% if
they are only refilling it in a manner to take it once daily
in a regular fashion, or could have been taking it twice
daily until they simply stopped taking and refilling the
medication half way through the prescribed refills, taking
zero medications daily after no longer refilling. For each
patient, a CMG was calculated for each class of antihyper-
tensive medications (including potentially 11 classes, such
as ace-inhibitors, thiazide diuretics, and beta-blockers).
Next, a composite CMG (as a continuous measure) was
calculated for all the antihypertensive medications, ex-
cluding loop diuretics because this class could be taken
for reasons beyond BP control (such as congestive heart
failure). Further details of the algorithm we used to
calculate the CMG are provided in the Appendix includ-
ing adjustment for automatic first fills of a new prescrip-
tion by VA pharmacies. A dichotomous measure was also
created to identify patients with significant non-adherence
refill gaps of CMG ≥ 20% (versus <20%).
2. Provider assessment of patient’s medication adherence
The primary care providers completed a post-visit ques-
tionnaire. This study focused on their responses to 2 ques-
tions requiring them to assess the patient’s adherence to
BP medications.
In the first question, providers were asked “how often
does your patient adhere to the BP regimen?” with scoring
options on a Likert scale from 1 (“none of the time”) to a
score of 5 (“all of time”). In the second question, providers
were asked “how much does adherence make it difficult to
control this patient’s BP?” with scoring options from 1
9 Veterans Affairs (VA) clinic sites in 3 states, 
in which 126 eligible providers were approached, 
who saw patients at least 2 half days per week
Eligible but declined:  22 providers
Became ineligible with job changes: 12 providers
1556 potential study patients assessed for eligibility
92 primary care providers (PCPs) recruited:
64 physicians, 
7 physician-assistants, 
21 nurse-practitioners
Excluded:  387 patients
Ineligible:  213
Received primary diabetes care from  
non-participating PCP:  149
Triage blood pressure <140/90: 23
Did not have diabetes: 16
Impaired decision-making ability: 15
Visit was a non-primary care visit: 3
Nursing home resident: 2
Enrolled in another research study: 2
Blood pressure at triage was taken only 
by provider: 2
Did not speak English: 1
Eligible but declined:  174 patients 
1169 patients recruited
1064 patients with at least one 
chronic BP medication refilled at VA
Excluded:  105 patients had never refilled a 
chronic BP medication at VA pharmacy
Figure 1 Study flow diagram.
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(“not at all”) to a score of 5 (“a great deal”). To generate a
continuous measure of provider assessment of adherence,
the responses to these questions were summed for a total
score of 2–10, after reverse scoring for similar directiona-
lity, and imputation of a few missing responses by recor-
ding the same level of score from an answered question to
be the response to the unanswered question. If the pro-
vider had not answered either question but the patient
was taking BP medications, the questions were imputed
by scoring the average response (3) for both questions.
Next we generated a dichotomous version of this in
which the provider was given credit for recognizing sig-
nificant non-adherence if a provider reported the patient
was taking medications “none of time” (score 1) or close
to it (score 2), or if the provider indicated that adherence
made the patient’s BP difficult to control by “a great deal”
(score 5) or close to it (score 4). Providers chose “don’t
know” or provided no assessment of adherence for 22
(8%) patients; no imputation was used to generate this
dichotomous variable.
3. Provider decision to intensify BP medications
In the post-visit survey, providers also answered ques-
tions regarding if and how the antihypertensive regimen
was changed at the visit; medication intensification (as a
dichotomous measure) was defined as providers adding or
increasing a BP medication dose without stopping another
medication or decreasing a dose [9]. For example, if the
provider indicated on the post-visit survey that she had
started a new BP medication but also discontinued a dif-
ferent BP medication, this would not count as intensifica-
tion. However, intensification would have occurred if the
provider started a new BP medication but did not either
discontinue or decrease another BP medication.
Statistical analyses
The primary analyses involved how providers assessed
each patient’s medication adherence in comparison to
each patient’s adherence according to refill records. First,
using continuous measures of provider assessment and
refill adherence, the strength of linear correlation bet-
ween the 2 measures was assessed. Then, using the
dichotomized measures for patients with significant non-
adherence, we assessed the concordance (or agreement)
between categorization of the pharmacy refill score as
non-adherent (CMG ≥ 20%) and being identified by the
provider as having significant non-adherence. We used a
2-sample t-test (accounting for unequal variances) to
assess significant differences between these 2 measures.
Our secondary analyses assessed the strength of asso-
ciation between the provider’s decision to intensify the
BP medication regimen (as a dependent, dichotomous
outcome) with the provider’s assessment of the patient’s
adherence (as an independent measure), explored using
both logistic regression (using the continuous measure
of provider assessment) and chi square statistics (using
the dichotomous measure of provider assessment). Co-
variates studied included the patient’s systolic and dias-
tolic BPs at triage, number of chronic antihypertensive
classes being prescribed at time of enrollment, total
number of chronic medication classes that a patient was
prescribed in the 90 days prior to enrollment and patient
self-reported characteristics of age, ethnicity, education,
annual income, monthly prescription costs, and marital
status.
All statistical analyses were performed using Stata
version 11.2 (Stata, College Station, Texas).
Results
Participant characteristics
Figure 1 outlines the study population recruitment of pro-
viders and patients. As summarized in the Table 1, the
lowest systolic BP of patients at enrollment had a mean of
154 mmHg (S.D. 14) and the lowest diastolic BP of
patients at enrollment was a mean of 78 mmHg (S.D. 12).
The mean age of the 1064 patients was 65 years (S.D. 11);
97% were men, 71% were white, and 54% were married.
Overall, the majority (76%) of patients reported an annual
income of < $40,000. Monthly prescription costs were
reported in a range of $0 (23%) to > $200 per month (6%),
with 39% of patients reporting monthly prescription costs
of > $50 per month. Patients were taking a mean of 2.9
classes of BP medications, and an average of 6.3 prescrip-
tion medications for all conditions at time of study enroll-
ment. Ninety-two primary care providers participated
with a mean age of 48, and a mean of 11.4 years in prac-
tice (range 1–33) including 64 physicians, 21 nurse practi-
tioners, and 7 physician assistants [9]; providers had a
median of 12 patients (range of 1–14) in the analyzed
study population.
Refill adherence scores (CMG)
The mean composite CMG for all BP medications for
our 1064 patients was 11.3% (S.D. 12%), signifying that,
on average, patients did not have adequate medication
supply to take as prescribed for 11% of days, or missed
11% of doses. As illustrated in the Figure 2, the
distribution of the CMG scores was highly skewed with
80% (N = 853) having a CMG score of < 20%, supporting
good refill adherence for most patients in this study
population of Veterans with diabetes. Thus, only 211
patients (20%) were categorized as significantly non-
adherent by their pharmacy refill scores with CMG≥ 20%.
Only 18 patients (1.7%) had a CMG score indicating
anticipated lack of supply for ≥ 50% of days/doses.
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Provider assessment of patient’s medication adherence
Provider responses to each of the 2 questions regar-
ding medication adherence had strong correlation (r = 0.7,
p < 0.0001) between questions, before and after imputation
of missing responses. Using the continuous summary
measure ranging from 2 (suggesting excellent adherence)
to 10 (suggesting very poor adherence), provider assess-
ments overall suggested good adherence, skewed
toward lower scores (illustrated in Figure 3). Of interest,
provider assessments of adherence of non-white patients
was somewhat higher (indicating worse adherence) with
mean score of 4.92 (95% CI= 4.35-5.48) compared to
Table 1 Patient characteristics
N, % of patients 1064, 100%
Demographics, by self-report Mean +/− SD Not answered: N (%)
N, %*
Age (range 33–88 years) Mean: 65 +/− 11 Not answered:107 (10%)
<45 16, 2%
≥ 45 & <65 464, 44%
≥ 65 & <75 257, 24%
≥ 75 220, 21%
Race Not answered: 96 (9%)
White 752 (71%)
Other 216 (20%)
Education Not answered: 104 (10%)
<High school 168 (16%)
High School / GED 350 (33%)
Some college or Trade School 337 (32%)
4 year degree 56 (5%)
Post-college 49 (5%)
Annual Income by self-report ($) Not answered: 162 (15%)
≤10,000 158 (15%)
>10,000 &≤ 20,000 287 (27%)
>20,000 &≤ 30,000 251 (24%)
>30,000 &≤ 40,000 112 (11%)
> 40,000 94 (9%)
Clinical characteristics, by medical record
Systolic Blood Pressure (BP): Mean: 154+/−14 No missing data.
>180 56 (5%)
160-180 252 (24%)
150-159 274 (26%)
140-149 455 (43%)
<140 27 (3%)
Diastolic Blood Pressure: Mean: 78 +/− 12 No missing data.
>100 31 (3%)
90-100 164 (15%)
80-89 281 (26%)
<80 588 (55%)
Number of BP med classes No missing data.
1-2 472 (44%)
3-4 455 (43%)
≥ 5 137 (13%)
* Percentages are rounded, so may not total 100%.
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provider assessments of white patients with a mean score
of 4.07 (95% CI= 3.87-4.28) even after adjusting for pa-
tient age, refill adherence (CMG), and systolic BP. Provi-
ders assessed 258 (24%) patients as having significant
non-adherence (using the dichotomous measure) with BP
medications by either post-visit question.
Comparing provider assessment with refill adherence
scores (CMG)
Overall, there was weak correlation (r = 0.18, p < 0.001)
between the patient’s refill adherence score and the
provider’s assessment of patient adherence.
Using dichotomized measures, a similar proportion of
patients was categorized as non-adherent by the gap
(CMG≥ 20%) in pharmacy refills (N= 211, 20%) and by
providers (N=258, 24%); yet, the dichotomized CMG
measure and the provider assessment were often identi-
fying significant non-adherence for different patients, as
illustrated in Figure 4. Providers appeared to recognize
significant non-adherence for only 79 (37%) of the 211
patients who had a CMG≥ 20%. Among the 18 patients
with very large medication refill gaps (CMGs≥ 50%), pro-
viders assessed 8 (44%) as non-adherent. Overall, the
mean CMG for patients categorized by providers as
having significant non-adherence was 14% (SD 14%), com-
pared with the mean CMG of 10% for patients (SD 11%)
for those not identified by providers with significant
adherence problems. Quantitative analysis for agreement
for the dichotomous categorization of the patient as hav-
ing poor adherence or not, as indicated by the provider
and pharmacy record, were also evaluated using kappa
statistics [16]. In general, there was only slight agreement
between the categorization by provider and pharmacy
record (kappa 0.15).
Provider decisions to intensify BP medications
Overall, providers intensified BP medications for 451 of
the 1064 patients (42%) at the study visit. Using logistic
regression with the provider decision to intensify as the
dependent variable, the provider’s assessment of adhe-
rence (as a continuous, independent variable) was not
predictive of the decision to intensify (OR 0.96, p = 0.25).
Of the covariates studied (systolic BP, age, race, refill gap),
only higher systolic BP (per 10 mm-Hg pressure increase)
was significantly associated with the provider’s decision
to intensify medications (OR 1.40, p < 0.0001, 95% CI
1.26-1.55).
Of the 258 patients identified by the provider as having
significant non-adherence, providers intensified medica-
tions for 113 (44%) of these patients; similarly, providers
intensified medications for 42% of patients that were not
identified by providers as having significant non-adherence.
Overall, there was no significant difference in providers’
decisions to intensify medications whether providers had
assessed patients as adherent or not.
Discussion
In this sample, primary care providers’ assessments of
adherence did not agree with more objective pharmacy
fill assessments about half of the time. In general,
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Figure 2 Provider Assessment of Adherence (Histogram).
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providers overestimated adherence with antihypertensive
medications, and were still less accurate in identifying
cases of significant non-adherence than a coin toss [17].
Unawareness and/or inaccuracy of physician assessment
of adherence to antihypertensiveshas been documented in
prior studies [18,19]. Yet, unlike these prior studies of
physician assessment of adherence performed, the VA
providers in this study could electronically review VA
pharmacy refill records of medications prescribed at VA at
the time of the visit. Despite these available VA pharmacy
records, providers still overestimated adherence with anti-
hypertensives. Admittedly, review of such refill records
can be time-consuming and hard to interpret as this task
requires physicians to examine long lists of medications or
to pull up specific graphs of refill patterns for individual
medications of interest. Given the multiple chronic condi-
tions and treatment goals that primary care providers
must consider in often brief primary care visits, these
results suggest that making medication adherence
assessments easier and quicker to interpret by providing
a simpler objective measure (such as the CMG or a related
measure using shorter time intervals known as ReComp
[10]) may help increase awareness of self-management
challenges by the provider and patient. The availability of
such real-time measures could serve as an important
step of patient-centered care to improve translation
of evidence-based treatment recommendations into
improved individual patient outcomes.
Other studies have shown doctors often intensify medi-
cations without inquiry and/or awareness of a patient’s
poor adherence to prescribed medications [8,20]; yet, ours
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Provider Summary Score (2 = excellent adherence, 10 = very poor adherence)
Mean Provider Summary Score = 4.4 with SD 2.2 (Median 4)
Figure 3 Comparing Identification of Significant Non-adherence by Provider Assessment and Refill History (CMG= Continuous
Multiple-interval Gap measure).
Figure 4 Comparing Identification of Significant Non-adherence
by Provider Assessment and Refill History (CMG= Continuous
Multiple-interval Gap measure).
Area A (circle outlined with solid border): 258 (24%) patients
identified by provider as having significant non-adherence.
Area B (circle outlined by dashed border): 211 (20%) patients
identified by refill measure (CMG≥ 20%) as having significant
non-adherence. Area C (overlap of areas A and B): 79 (7%) patients
identified as having significant non-adherence by both the provider
assessment and refill measure (CMG). Area D (surrounding gray
box): 674 patients without evidence of non-adherence by either
provider assessment or refill measure (CMG), including 22 patients
for whom the providers did not provide an adherence assessment
by either post-visit question.
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is the first to demonstrate that providers often intensified
BP medications even when providers did suspect serious
adherence problems. This implies that providers may have
more confidence in their ability to improve BP by intensi-
fying medications rather than addressing adherence issues.
Providers may also be simply prioritizing medication
intensification rather than evaluating and addressing
adherence. For example, providers may be responding to
monitored performance measures regarding BP control by
intensifying medications because attempting to improve
adherence can prove to be difficult and time-consuming.
This suggests that better systems approaches are needed
to improve medication adherence that do not rely on indi-
vidual PCPs.
Traditional wisdom teaches that intensifying prescrip-
tion regimens in non-adherent patients poses additional
risk to patients (such as adverse events of dizziness and
low BP, should a previously non-adherent patient start
taking a higher dose medication regimen) and prior
studies have supported lack of better outcomes when
medication intensification occurs without concurrent
improvement of medication adherences [8,20]. Yet, more
recent studies have suggested some improvement in BP
control with intensification regardless of the patient’s level
of adherence [21]. The potential hazards and benefits of
intensifying a regimen in the outpatient setting of prior
poor adherence are complicated and difficult to study.
For example, it is not uncommon for patients with poor
adherence in the outpatient setting to be admitted with
elevated blood pressure, then prescribed multiple antihy-
pertensives on a scheduled and observed basis while ad-
mitted, leading to significant hypotension with dizziness,
increased risk of falling and inadequate renal perfusion -
requiring acute treatments to reverse hypotension (i.e., IV
fluids, pressors) which are also not without risk. However,
in the outpatient setting, sudden perfect adherence of an
intensified regimen is likely to occur only in the setting
of an additional intervention such as medication adminis-
tration by family members or visiting nurses. Thus, it is
possible that a previously poorly adherent patient would
experience a smaller positive impact on blood pressure
with an intensification of the regimen (even if only taking
50% of the doses) due to imperfect medication taking at
baseline [21]. On the other hand, side effects of outpatient
hypotension in response to intensified regimens may not
be well reported, particularly if providers do not ask about
potential signs and symptoms of hypotension. Of note, the
recent study by Rose et al. [21] reporting improved BP
after intensification in patients with poor adherence did
not report patient outcomes such as side effects from
hypotension.
Some limitations of the study should be noted. Overall,
this study population of VA patients with diabetes and
uncontrolled hypertension had high refill adherence,
with only 20% of patients with a CMG >20%; this high
adherence may generate concerns for generalizability of
our results. However, similarly high levels of BP medica-
tion adherence have recently been reported for Medi-
care, managed care, and urban safety net populations
[13,21,22]. Also, admittedly, refill adherence is a conser-
vative measure of medication-taking adherence because
possession of medications alone does not mean patients
are actually taking the medications as prescribed. Like-
wise, a physician’s assessment of a patient as non-adherent
does not refer specifically to the physician’s opinion of the
patient’s refill adherence, but instead is an assessment of
their overall adherence with taking the prescribed
medications. Accounting for this, we focused several of
our analyses on patients who were first identified as not
possessing the medications (CMG≥ 20%), because it was
assumed that if the patient wasn’t refilling the medication
then the patient also couldn’t actually be taking the medi-
cation as prescribed. This seems a reasonable assumption
for VA patients at the time of this study before many of
the low-cost generic retail pharmacy programs were
developed in late 2006. Another important limitation is
that providers were asked to assess patient adherence in a
post-visit questionnaire; therefore, it is possible that for
some patients, the providers had not actually contem-
plated patient adherence before making medication treat-
ment decisions during the visit such as whether to
intensify or not. Yet, this aspect of our study also mirrors
clinical practice, as providers are not required to systema-
tically assess adherence prior to implementing manage-
ment changes.
General limitations using the CMG measure of refill
adherence should also be noted. In order for our phar-
macy adherence measure to better reflect adherence as
indicated by refills the patient requested, we excluded
new medications with only one fill from the calculation
because first prescriptions in the VA health system are
filled automatically without effort required by the pa-
tient, and because single fill medications could represent
a trial of new medication. Yet, we acknowledge that
exclusion of medications with a single fill may decrease
detection of the most non-adherent patients who did
not fill any antihypertensive medications past the auto-
mated first fill. In evaluating for potential impact of
missing such patients in our dataset, 558 (15%) of 3695
prescriptions were excluded from our analyses because
of no additional refills initiated; yet, most of these
patients had additional BP prescriptions that did have
refills that kept the patient included in the dataset for
analysis. Another potential limitation of the CMG meas-
ure is loss of information regarding over-supply sources
if only outpatient pharmacy data is employed; keeping
this in mind, our method for CMG calculation was spe-
cifically tailored to account for multiple sources of
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oversupply by also utilizing inpatient records regarding
hospitalizations and discharge medications.
Conclusions
In summary, despite medication non-adherence being
an important and modifiable barrier to improving BP
control, PCPs do not accurately detect significant non-
adherence by traditional clinical assessment alone. Inac-
curate physician assessment of patient adherence has
important implications for patient care, including poten-
tial harm to patients by continuing to intensify medica-
tion regimens despite inconsistent medication taking
and missed opportunities for identifying and addressing
patient barriers to self-management. Although pharmacy
refill adherence is only one aspect of adherence to treat-
ment for hypertension, this type of data is an important
objective measure of adherence that may serve as a screen-
ing test for detecting and prompting discussion and inter-
vention regarding non-adherence to chronic medications.
Appendix
Algorithm for Refill Adherence Measure Calculation:
Continuous Multiple-Interval Gap (CMG) Measure
Our CMG measure was calculated using the following
algorithm, illustrated in Appendix Figure 5:
1. Looking retrospectively 12 months from the patient’s
clinic visit, our VA pharmacy record details specific
dates of when a medicine was first filled, dates of
each fill and refill (noted by thin arrows in Appendix
Figure 5), and days of supply the prescription would
last if taken as prescribed (shaded boxes in Appendix
Figure 5). For the purpose of determining if the
patient was already taking a medication chronically
prior to the 12 month observation period (and when
it would be expected to require refill within the
12 month observation period), prescription records
were also evaluated for 90 days prior to the
12 month observation period. For the purpose of
determining if medications not refilled recently prior
to the time of the appointment were inappropriately
late refill requests, or if these medications were not
expected to be continued chronically, prescription
refill records were also evaluated for 90 days after the
clinic visit.
2. Next, if the patient was taking the medicine exactly
as prescribed at full dose, which date would the
patient expected to be without medication (“supply
end” noted by * in Appendix Figure 5).
3. Then, all days that occur between the date of supply
end and the next refill date are considered to be “gap
days” (white boxes in Appendix Figure 5), that is,
days where the patient would be expected to be
experiencing a gap in medication supply because had
not refilled early enough.
4. To generate the CMG for each BP medication class, the
total number of gap days for medications in each class
was summed, and then divided by the total number of
days that patient was prescribed the medications in that
class, to yield the following measure:
Total gap days
Total prescribed days End Startð Þ ¼ CMG
¼ % of days without medication supply
CMG = Continuous Multiple-interval Gap measure
              Total gap days                =  % of days without
Total prescribed days (End-Start)      medication supply
-6 months
Clinic 
Visit
-12 months
Rx start,
Fill #1 Rx endFill #2 Fill #3
90 day supply 25 gap days 90 day supply 70 gap days 90 day supply
Supply 
Ends
Supply 
Ends
∗ ∗ ∗
Total gap days = 25+70     = 95 days  = 0.26 = 26% days without medication supply
      End-Start = 365 days     365 days
Figure 5 Example of Calculation of Refill Adherence Measure.
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5. To generate the composite CMG, the total number
of gap days for all BP medications (all classes,
excluding loop diuretics for reasons explained below)
was summed, and then divided by the total number
of days the patient was prescribed each medication.
Therefore, the composite CMG is not a simple
average of the CMG calculated for each BP
medication class; instead, it takes into account
(and thus is weighted by) the duration of time the
patient was prescribed each medication. Thus,
a single medication (or a single class) of short
duration would not have equal influence as a
long-standing chronically prescribed BP medication.
This ratio of total gap days to total prescribed days
yields the CMG, which is measure of proportion of days
without adequate medication, also known as a ratio of
non-possession. For example, a CMG of 0.2 or 20% means
the patient refilled the medication in a manner that left
20% of days without an adequate medication supply to
take. The CMG can also be interpreted as a proportion of
time the patient misses their medications, with a CMG
of 20% meaning that on average, the patient missed 20%
of the doses, or 1 day or dose in 5. Prior literature has
established that a lack of medication possession of ≥ 20%
is clinically significant refill non-adherence [14].
In order for our pharmacy adherence measure to bet-
ter reflect adherence as indicated by refills the patient
requested, we excluded new medications with only one
fill for the CMG calculation because first prescriptions
in the VA health system are filled automatically without
effort required by the patient. New medications were
identified as having a total expected supply to patient
of ≤ 90 days in the study period year, with less than 2
fills. Using the rich and connected VA database of in-
patient, outpatient, and pharmacy data, multiple sources
of oversupply were also accounted for, including days of
hospitalization and early refills which include early medi-
cation fills written as part of discharge orders [8,23].
Of note, our refill adherence measure including refill
data for all classes of antihypertensives excluding only
loop diuretics, because loop diuretics can be taken for rea-
sons such as congestive heart failure or edema with direc-
tions and instructions changing frequently by prescribers
to treat acute exacerbations (such as increased loop diure-
tic for 3–4 days, before transition to a stable dose). Thus,
the refill record for loop diuretics was not thought to re-
flect adherence as an antihypertensive treatment. In sum-
mary, classes of antihypertensives that were evaluated and
included for patients in this study included: angiotensin
converting enzyme (ACE) inhibitors, beta blockers, calcium
channel blockers, alpha receptor blockers, hydralazine, al-
dosterone receptor blockers, sympathetic blockers, thiazide
diuretics, potassium-sparing diuretics, renin-inhibitors, and
minoxidil.
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